John Michael Kaczmar, MD, medical oncologist, associate professor, College of Medicine, Medical University of South Carolina (MUSC), MUSC Health, discusses future implications forthe use of fianlimab (formerly REGN 3767) in combination with cemiplimab-rwlc (Libtayo) for the treatment of patients with advanced melanoma.
2023
Neoadjuvant Daromun Meets Primary End Point of RFS in Melanoma
A trial of intratumoral daromun and surgical resection for the treatment of patients with locally advanced, fully resectable melanoma, showed a clinically meaningful improvement compared with surgery alone.
FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma
Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.
Cancer drug restores immune system’s ability to fight tumors in animal studies
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found. In mouse models of melanoma, bladder cancer, leukemia and colon cancer, the drug slows the growth of tumors, extends lifespan and boosts the efficacy of immunotherapy.